Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANTIBIOBONTA antibiotic-sparing strategy before intravesical botulinum toxin A injections
2024-515107-19-00Phase 3Authorised
- Sponsor
- CHU de Lille
- Start
- Nov 2025
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of levofloxacin, trimethoprim + sulfamethoxazole, pivmecillinam, aztreonam, cefixime and 8 more in asymptomatic bacteriuria (ASB) and urinary tract infection (UTI) (2 arms), sponsored by CHU de Lille. Primary endpoint: Rate of symptomatic urinary tract infection within 6 weeks. Planned start Nov 2025; status: authorised.
02
Drugs
levofloxacintrimethoprim + sulfamethoxazolepivmecillinamaztreonamcefixime
03
Conditions
asymptomatic bacteriuria (ASB)urinary tract infection (UTI)
Beyond the preview
Go deeper on 2024-515107-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515107-19-00.